1116652-02-8

Basic information

• Product Name: N-(2-chloroquinolin-4-yl)cyclohexanecarboxamide
• Synonyms: N-(2-chloroquinolin-4-yl)cyclohexanecarboxamide
• CAS NO: 1116652-02-8
• Molecular Weight: 288.777
• Mol File: 1116652-02-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(2-chloroquinolin-4-yl)cyclohexanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-chloroquinolin-4-yl)cyclohexanecarboxamide(1116652-02-8)
• EPA Substance Registry System: N-(2-chloroquinolin-4-yl)cyclohexanecarboxamide(1116652-02-8)

Safety Data

• Hazardous Substances Data: 1116652-02-8(Hazardous Substances Data)

Upstream product

• 80947-25-7 2-chloroquinoline-4-amine 
• 2719-27-9 cyclohexanylcarbonyl chloride 

Downstream Products

• 1116652-20-0 N-[2-(2,3-dihydro-1H-inden-5-ylamino)quinolin-4-yl]cyclohexanecarboxamide 
• 1116652-19-7 N-{2-[(4-methylphenyl)amino]quinolin-4-yl}cyclohexanecarboxamide 
• 1116652-17-5 N-(2-anilinoquinolin-4-yl)cyclohexanecarboxamide 
• 1116652-18-6 LUF₆₀₉₆ 

Relevant articles and documents

A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS

The present invention provides 2,4-disubstituted quinoline derivatives being an A3 adenosine receptor modulator (A3RM), for use in the treatment of a condition which is treatable by adenosine, an A3 adenosine receptor (A3AR) agonist or an A3 adenosine receptor antagonist. In one embodiment, the 2,4-disubstituted quinoline derivatives are for use in the treatment of a condition treatable by an adenosine or an A3AR agonist, treatment being achieved by enhancing activity of a protein (by binding of said 2,4 disubstituted quinoline derivative to the A3AR). Some conditions treatable by the 2,4 disubstituted quinoline derivative when used for enhancing activity include, malignancy, an immuno-compromised affliction, high intraocular pressure or a condition associated with high intraocular pressure. The invention also provides method for treatment of a subject having a condition treatable by adenosine, an A3AR agonist or an A3AR antagonist making use of the defined 2,4-disubstituted quinoline derivative (s), and pharmaceutical composition and comprising said derivative and a kit comprising the derivative and instructions for use thereof. One specific 2,4-disubstituted quinoline derivative comprises N-{2-[(3,4-dichlorophenyl)amino]quinolin-4-yl}cyclohexanecarboxamide In one embodiment, the 2,4-disubstituted quinoline derivatives in accordance with the invention are formulated in a form suitable for oral administration.